The Key to Unlocking the Chemotherapeutic Potential of PPARγ Ligands: Having the Right Combination

Table 2

In vivo and clinical trials synergistic effects between PPARγ ligands and other agents. Descriptions reflect most noteworthy finding of each study.

	Platinum-based compounds	Taxanes	Topoisomerase inhibitors	Anti-metabolites
Rosiglitazone	(i) ↓ Volume of A549 NSCLC xenografted tumours [31]
	(ii) ↓ Volume in KRAS- and EGFRdriven lung tumours without disrupting immune system [57]
	(iii) ↓ Volume and ↑ differentiation of DMBA-induced breast tumours; treatment minimized nephrotoxicity [32] *pre-treatment
Troglitazone	(i) ↓ Volume and ↑ overall survival of EHMES-10 malignant pleural mesothelioma xenografted tumours [34]
Pioglitazone				Phase 2 clinical trial: (i) 30% of patients with high grade gliomas experienced disease stabilization; treatment well tolerated by all [58]
RS5444		(i) ↓ Volume of DRO90-1 and ARO81 anaplastic thyroid carcinoma xenografted tumours [53]
15d-PGJ2		(i) ↓ Volume of A549 and H460 NSCLC xenografted tumours [54]
LY 293111			Phase 1 clinical trial: (i) ↓ GI toxicity in patients with advanced; solid tumours [59]	(i) ↓ Volume of S2-013 pancreatic xenografted tumours; minimized side effects [60]